Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: a report of two cases
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease that can lead to severe destruction of the jaw. As there is no standard protocol for treating MRONJ, various treatments have been studied. Teriparatide has been used as an adjunct therapy for MRONJ. However, its effectiveness has not been sufficiently demonstrated for use as a standard treatment for MRONJ. This study aimed to demonstrate the efficacy of teriparatide in treating MRONJ by presenting two successfully treated cases. Each patient received teriparatide therapy with surgical intervention. The appropriateness of teriparatide use was evaluated based on the patient’s systemic condition, and the administration of teriparatide was supervised by a physician. Complete resolution of the lesion was observed clinically and radiographically in both patients. The first patient underwent implant placement at the lesion site. Due to its anabolic properties and ability to stimulate bone remodeling, teriparatide is an effective adjunctive pharmacological treatment for bone healing before and after surgery with associated beneficial effects on bone and mucosal healing.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease that can lead to severe destruction of the jaw. As there is no standard protocol for treating MRONJ, various treatments have been studied. Teriparatide has been used as an adjunct therapy for MRONJ. However, its effectiveness has not been sufficiently demonstrated for use as a standard treatment for MRONJ. This study aimed to demonstrate the efficacy of teriparatide in treating MRONJ by presenting two successfully treated cases. Each patient received teriparatide therapy with surgical intervention. The appropriateness of teriparatide use was evaluated based on the patient’s systemic condition, and the administration of teriparatide was supervised by a physician. Complete resolution of the lesion was observed clinically and radiographically in both patients. The first patient underwent implant placement at the lesion site. Due to its anabolic properties and ability to stimulate bone remodeling, teriparatide is an effective adjunctive pharmacological treatment for bone healing before and after surgery with associated beneficial effects on bone and mucosal healing.
참고문헌 (24)
- Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update", J Oral Maxillofac Surg, 80, pp.920~943 (2022)[DOI]
- Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)[DOI]
- Canalis E, "Management of endocrine disease : novel anabolic treatments for osteoporosis", Eur J Endocrinol, 178, pp.R33~R44 (2018)[DOI]
- Chen T, "Parathyroid hormone and its related peptides in bone metabolism", Biochem Pharmacol, 192, pp.114669~ (2021)[DOI]
- de Souza Tolentino E, "Adjuvant therapies in the management of medication-related osteonecrosis of the jaws : systematic review", Head Neck, 41, pp.4209~4228 (2019)[DOI]
- "J Oral Maxillofac Surg", 2007, 573~580, 10.1016[DOI]
- Kim KM, "Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw", Osteoporos Int, 25, pp.1625~1632 (2014)[DOI]
- Zushi Y, "Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants : a case report", Int J Implant Dent, 3, pp.11~ (2017)[DOI]
- Choi SY, "Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw : a report of three cases", J Korean Assoc Oral Maxillofac Surg, 50, pp.103~109 (2024)[DOI]
- Kim KM, "Effects of daily versus weekly teriparatide for medicationrelated osteonecrosis of the jaw : a case-control study", Oral Dis, 30, pp.3286~3295 (2024)[DOI]
- Sim IW, "Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw : a placebo-controlled, randomized trial", J Clin Oncol, 38, pp.2971~2980 (2020)[DOI]
- Adami G, "Osteoporosis in 10 years time : a glimpse into the future of osteoporosis", Ther Adv Musculoskelet Dis, 14, pp.1759720X221083541~ (2022)[DOI]
- Shim GJ, "Current trends in adjuvant therapies for medication-related osteonecrosis of the jaw", Appl Sci, 12, pp.4035~ (2022)[DOI]
- Dos Santos Ferreira L, "Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis", Osteoporos Int, 32, pp.2449~2459 (2021)[DOI]
- Anabtawi M, "The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw", Int J Oral Maxillofac Surg, 50, pp.501~510 (2021)[DOI]
- "FORTEO (teriparatide injection)"[URL]
- Mohammad Ismail SH, "Teriparatide use in the treatment of severe hypocalcemia after kidney transplantation : a case report", Kidney Transplant Transplant Immunol, 8(3 Suppl), pp.S395~ (2023)[DOI]
- Krege JH, "Teriparatide and osteosarcoma risk : history, science, elimination of boxed warning, and other label updates", JBMR Plus, 6, pp.e10665~ (2022)[DOI]
- Andrews EB, "The US postmarketing surveillance study of adult osteosarcoma and teriparatide : study design and findings from the first 7years", J Bone Miner Res, 27, pp.2429~2437 (2012)[DOI]
- Burckhardt P, "Fractures after denosumab discontinuation : a retrospective study of 797 cases", J Bone Miner Res, 36, pp.1717~1728 (2021)[DOI]
- Leder BZ, "Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study) : extension of a randomised controlled trial", Lancet, 386, pp.1147~1155 (2015)[DOI]
- Anastasilakis AD, "Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation : systematic review and additional cases", J Bone Miner Res, 32, pp.1291~1296 (2017)[DOI]
- Ristow O, "Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study", J Craniomaxillofac Surg, 47, pp.491~499 (2019)[DOI]
- Black DM, "Clinical practice. Postmenopausal osteoporosis", N Engl J Med, 374, pp.254~262 (2016)[DOI]